Last reviewed 2026-06-01 · How we verify

Bupranol (BUPRANOLOL)

Phase 2 active Small molecule ✓ Verified Jun 2026 Quality 31/100

Bupranol (generic name: BUPRANOLOL) is a bupranolol drug. It is currently in Phase 2 development for Glaucoma, Hypertensive disorder.

Bupranol works by blocking the beta-2 adrenergic receptor, which helps to reduce the pressure in the eye and lower blood pressure.

Bupranol is a small molecule with the synonyms B 1312 FREE BASE, B-1312 FREE BASE, BUPRANOLOL, BUPRANOLOL, KL-255 FREE BASE, and OPHTORENIN.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BUPRANOLOL
Drug class	bupranolol
Target	Beta-2 adrenergic receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock. The beta-2 adrenergic receptor is like a lock on a door, and Bupranol is the key that blocks it from being opened. When this lock is blocked, the pressure in the eye and blood pressure are reduced, which can help to treat glaucoma and hypertensive disorders.

Approved indications

Glaucoma
Hypertensive disorder

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bupranol CI brief — competitive landscape report
Bupranol updates RSS · CI watch RSS

Frequently asked questions about Bupranol

What is Bupranol?

Bupranol (BUPRANOLOL) is a bupranolol drug, indicated for Glaucoma, Hypertensive disorder.

How does Bupranol work?

Bupranol works by blocking the beta-2 adrenergic receptor, which helps to reduce the pressure in the eye and lower blood pressure.

What is Bupranol used for?

Bupranol is indicated for Glaucoma, Hypertensive disorder.

What is the generic name of Bupranol?

BUPRANOLOL is the generic (nonproprietary) name of Bupranol.

What drug class is Bupranol in?

Bupranol belongs to the bupranolol class. See all bupranolol drugs at /class/bupranolol.

What development phase is Bupranol in?

Bupranol is in Phase 2.

What does Bupranol target?

Bupranol targets Beta-2 adrenergic receptor and is a bupranolol.

Drug class: All bupranolol drugs
Target: All drugs targeting Beta-2 adrenergic receptor
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Glaucoma
Indication: Drugs for Hypertensive disorder

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing